newsfilter
← Earnings
Earnings Releases·

Invivyd — Third Quarter 2026 Earnings Summary

  • Financial Performance:

    • Q3 2026 net product revenue was $15.4 million, an 18% increase compared to $13.1 million in Q3 2025.
    • Nine months ended September 30, 2026, total revenue was $43.5 million, up from $36.2 million in the same period of 2025.
    • Q3 2026 Research and Development (R&D) expenses were $18.7 million, compared to $8.0 million in Q3 2025, driven by higher contract research costs for the DECLARATION and LIBERTY trials.
    • Q3 2026 Selling, General & Administrative (SG&A) expenses were $30.3 million, compared to $15.0 million in Q3 2025, attributed to increased personnel, communications, and commercial costs.
    • Q3 2026 Net loss was $33.5 million, compared to $10.5 million in Q3 2025.
    • Q3 2026 Net loss per share (basic and diluted) was $0.10, compared to $0.06 in Q3 2025.
    • Cash and cash equivalents were $126.4 million as of September 30, 2026, down from $226.7 million as of December 31, 2025.
    • Total operating costs and expenses for Q3 2026 were $50.1 million, compared to $24.2 million in Q3 2025.
  • Guidance and Future Outlook:

    • DECLARATION Phase 3 clinical trial data for VYD2311 is expected imminently to support a Biologics License Application (BLA) submission under the Accelerated Approval Program.
    • Invivyd plans to host a Medical and Commercial Investor Event in the first half of 2027 to detail commercial plans and early institutional demand for VYD2311.
    • The company anticipates a new posture of increased operating efficiency following the completion of the REVOLUTION clinical program spend.
    • The Emergency Use Authorization (EUA) for PEMGARDA is scheduled to terminate on June 29, 2027, following a twelve-month notice received in July 2026.
    • Production scaling for the measles candidate VMS063 is underway to support clinical development in 2027.
  • Business Segments and Product Lines:

    • PEMGARDA (pemivibart): Net product revenue growth of 18% in Q3 2026 was driven by increased patient demand despite declining COVID vaccine utilization.
    • VYD2311 (ibramvibart):
      • LIBERTY Phase 3 trial results announced in September 2026 showed VYD2311 safety and tolerability superior to an mRNA-based COVID-19 vaccine.
      • LIBERTY data confirmed VYD2311 combined with mRNA vaccines did not interfere with vaccine-induced neutralizing antibody titers and added substantially to them.
      • FLINTLOCK Phase 2 trial initiated in October 2026 to evaluate VYD2311 in adults aged 18-65 with Long COVID or Post-Vaccination Syndrome.
    • VMS063: A novel measles monoclonal antibody candidate presented at IDWeek 2026, demonstrating potent in vitro activity against contemporary measles variants.
  • Market and Competitive Landscape:

    • PEMGARDA demonstrated in vitro neutralizing activity against major SARS-CoV-2 variants including JN.1, KP.3.1.1, XEC, LP.8.1, and XFG.
    • The company positions VYD2311 as a potential first-and-best-in-class option for Long COVID and Post-Vaccination Syndrome treatment.
    • VMS063 is described as a potential first precision therapy for measles, designed to supplement or enhance measles vaccination.
  • Risks and Challenges:

    • The EUA for PEMGARDA is set to terminate on June 29, 2027, creating a transition period risk.
    • Regulatory uncertainty exists regarding the timing of the DECLARATION data readout and the specific details of the Accelerated Approval approach.
    • Future revenue is subject to uncertainties regarding market acceptance, payor coverage, and reimbursement for authorized or approved products.
    • Risks include potential emergence of SARS-CoV-2 variants with substantially reduced susceptibility to PEMGARDA and VYD2311.
    • The company faces risks related to the success of clinical trials, regulatory approval processes, and the ability to maintain an acceptable safety and efficacy profile.
  • Management Commentary and Tone:

    • Marc Elia, Chairman and CEO, expressed excitement about advancing VYD2311 to meet the urgent need for new options against COVID-19 and Long COVID.
    • Elia noted that U.S. regulators understand the important role monoclonal antibodies play in infectious disease and expressed appreciation for investor patience during regulatory dialogue.
    • CFO Bill Duke highlighted PEMGARDA's continued growth despite the upcoming EUA termination and the company's focus on increased operating efficiency.
    • Management emphasized the clinical superiority of VYD2311's safety profile compared to mRNA vaccines as a key differentiator.
  • Other Key Points:

    • Marc Elia was appointed Chief Executive Officer in September 2026.
    • Ajay Royan was appointed Lead Independent Director, and Ian Sheffield was appointed as an independent director to the Board.
    • The DECLARATION trial is designed to serve as the basis for a BLA submission under the Accelerated Approval Program, with interim analysis data expected imminently.
    • The FLINTLOCK trial will assess high-dose VYD2311 administered in three doses over 90 days versus placebo.
    • The company has invested in commercial preparedness for VYD2311.
Company
INVIVYD INC
Sector
Healthcare
Industry
Biotechnology